T

TriSalus Life Sciences Inc
NASDAQ:TLSI

Watchlist Manager
TriSalus Life Sciences Inc
NASDAQ:TLSI
Watchlist
Price: 4.07 USD 0.25%
Market Cap: 124.1m USD
Have any thoughts about
TriSalus Life Sciences Inc?
Write Note

Net Margin
TriSalus Life Sciences Inc

-217.9%
Current
-136%
Average
3.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-217.9%
=
Net Income
-72.7m
/
Revenue
33.3m

Net Margin Across Competitors

Country US
Market Cap 123.7m USD
Net Margin
-218%
Country CA
Market Cap 559.6B CAD
Net Margin N/A
Country US
Market Cap 94.8B USD
Net Margin
4%
Country NL
Market Cap 85B Zac
Net Margin
63%
Country US
Market Cap 39.9B EUR
Net Margin
4%
Country ID
Market Cap 650.9T IDR
Net Margin
27%
Country US
Market Cap 29.8B USD
Net Margin
-48%
Country CH
Market Cap 23B CHF
Net Margin
-1%
Country IN
Market Cap 1.9T INR
Net Margin
123%
Country ZA
Market Cap 21.3B Zac
Net Margin
99%
Country ZA
Market Cap 19.1B Zac
Net Margin
116%
No Stocks Found

TriSalus Life Sciences Inc
Glance View

Market Cap
124m USD
Industry
N/A

TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.

TLSI Intrinsic Value
3.66 USD
Overvaluation 10%
Intrinsic Value
Price
T

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-217.9%
=
Net Income
-72.7m
/
Revenue
33.3m
What is the Net Margin of TriSalus Life Sciences Inc?

Based on TriSalus Life Sciences Inc's most recent financial statements, the company has Net Margin of -217.9%.